超氧化物歧化酶（SOD）、氧化蛋白产物（AOPP）和疾病修正治疗与多发性硬化症患者接受皮质类固醇治疗后的更好的复发缓解相关。

Superoxide dismutase (SOD), advanced oxidation protein products (AOPP), and disease-modifying treatment are related to better relapse recovery after corticosteroid treatment in multiple sclerosis.

机构信息

Neurology Clinic, Military Medical Academy, Faculty of Medicine, University of Defense, Belgrade, Serbia.

Institute of Medical Biochemistry, Military Medical Academy, Faculty of Medicine, University of Defense, Belgrade, Serbia.

出版信息

Neurol Sci. 2021 Aug;42(8):3241-3247. doi: 10.1007/s10072-020-04928-y. Epub 2020 Nov 26.

DOI:10.1007/s10072-020-04928-y

PMID:33241537

Abstract

OBJECTIVES

The aim of our study was to analyze oxidative stress (OS) markers in multiple sclerosis (MS) patients during relapse and remission and to evaluate the effects of corticosteroid relapse treatment on oxidative status, and also to determine possible relationship between OS markers and relapse disability recovery after corticosteroid treatment.

METHODS

Our study included 118 MS patients, (59 relapse/59 remission) 70 females and 48 males, mean age 40.2 ± 9.4 years, and 88 matched healthy controls. Undergoing disease-modifying therapy (DMT) was present in 30.5% of relapse and 88% of remission MS patients. We analyzed in plasma/serum the following: pro-oxidative-antioxidative balance (PAB), nitrates and nitrites (NO + NO), malondialdehyde (MDA), advanced oxidation protein products (AOPP) superoxide dismutase (SOD), catalase (CAT), uric acid, bilirubin, albumin, and transferrin in all patients and additionally after corticosteroid relapse treatment. Neurological disability was measured using the Extended Disability Status Scale (EDSS).

RESULTS

Better clinical recovery after relapse treatment was associated with increased baseline SOD, decreased AOPP, and ongoing DMT (all p < 0.05). There was no difference between OS markers in relapse and remission. MS patients had higher MDA, NO + NO, PAB, SOD, CAT, lower AOPP, uric acid, albumin, bilirubin, and transferrin compared to controls (all p < 0.05). Corticosteroids caused significant decrease of all OS markers (all p < 0.05).

CONCLUSION

Increased baseline antioxidative activity of SOD and decreased baseline levels of pro-oxidant AOPP along with ongoing DMT were related to better clinical recovery after corticosteroid relapse treatment. Increase of pro-oxidants and antioxidant enzyme activity in relapse and remission confirms ongoing oxidative injury irrelevant of MS clinical presentation.

摘要

目的

本研究旨在分析多发性硬化症（MS）患者在复发和缓解期的氧化应激（OS）标志物，并评估皮质类固醇复发治疗对氧化状态的影响，同时确定 OS 标志物与皮质类固醇治疗后复发残疾恢复之间的可能关系。

方法

我们的研究纳入了 118 名 MS 患者（59 名复发/59 名缓解），70 名女性和 48 名男性，平均年龄为 40.2±9.4 岁，88 名匹配的健康对照者。30.5%的复发患者和 88%的缓解患者正在接受疾病修正治疗（DMT）。我们在所有患者的血浆/血清中分析了以下指标：促氧化剂-抗氧化剂平衡（PAB）、硝酸盐和亚硝酸盐（NO+NO）、丙二醛（MDA）、高级氧化蛋白产物（AOPP）、超氧化物歧化酶（SOD）、过氧化氢酶（CAT）、尿酸、胆红素、白蛋白和转铁蛋白，此外还分析了皮质类固醇复发治疗后的上述指标。采用扩展残疾状况量表（EDSS）测量神经功能障碍。

结果

复发治疗后的临床恢复更好与基线 SOD 增加、AOPP 降低以及持续 DMT 有关（均 p<0.05）。复发和缓解期 OS 标志物无差异。MS 患者的 MDA、NO+NO、PAB、SOD、CAT 较高，AOPP、尿酸、白蛋白、胆红素和转铁蛋白较低，与对照组相比差异均有统计学意义（均 p<0.05）。皮质类固醇治疗后所有 OS 标志物均显著降低（均 p<0.05）。